Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

A Study To Evaluate The Persistence Of The Antibody Response Elicited By 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses Of 13vPnC Or 13vPnC And 23-Valent Pneumococcal Polysaccharide Vaccine In Different Sequential Order In Study 6115A1-3010 Or 6115A1 3005

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01025336

Acronym

AB PERSISTENCE

Enrollment

962

Registered

2009-12-03

Start date

2009-12-31

Completion date

2010-10-31

Last updated

2012-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Antibody persistence

Brief summary

The purpose of this study is to evaluate the levels of antibodies 1 year after receiving the second vaccine dose in two groups of adults over the age of 60: (1) those who have previously received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) and (2) those who have previously received 1 dose of 13vPnc and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). This study will also assess whether the use of the 2 vaccines, 13vPnC and 23vPS, administered in different sequential order results in different prolonged antibody levels. This study is limited to individuals who participated in either study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572).

Interventions

OTHERBlood draw

Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Only study volunteers who received both assigned vaccinations at visit 1 and visit 4 when they participated in either study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572)

Exclusion criteria

* Vaccination with any licensed or experimental pneumococcal vaccine since being enrolled in the 6115A1-3005 (NCT00546572) or 6115A1-3010 (NCT00574548) study (other than study vaccines permitted in 6115A1-3010 or 6115A1-3005)

Design outcomes

Primary

Measure	Time frame	Description
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CIs) for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CIs) for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers.

Secondary

Measure	Time frame	Description
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 1 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Month 0/Year 1 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Month 1/Year 0 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Month 1/Year 0 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 0 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Month 0/Year 0 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Month 1/Year 1 (Parent study/NCT00574548), Month 1/Year 2 (Follow-up Study/NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/23vPS 1 Year After Vaccination 2 Compared to 23vPS 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 1 (Parent Study NCT00574548), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 23vPS/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 1 (Parent Study NCT00574548), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 1 (Parent Study NCT00574548), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 23vPS/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC 1 Year After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Month 0/Year 1 (Parent Study NCT00546572), Month 1/Year 2 (Baseline; Follow-up Study NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Month 0/Year 1 (Parent Study NCT00546572), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC 1 Year After Vaccination 1 Compared to 23vPS 1 Year After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 1 (Parent Study NCT00574548)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC 1 Year After Vaccination 1 Compared to 23vPS 1 Year After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Month 0/Year 1 (Parent Study NCT00546572)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Month 1/Year 1 (Parent study/NCT00546572), Month 1/Year 2 (Follow-up Study/NCT01025336)	Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Countries

United States

Participant flow

Pre-assignment details

Only participants who completed Parent Study 6115A1-3010 (NCT00574548) or Parent Study 6115A1-3005 (NCT00546572) were enrolled in this follow-up study 6115A1-3018 (NCT01025336).

Participants by arm

Arm	Count
13vPnC/13vPnC Group (23vPS Naïve) Participants aged 60 to 64 years old who had never received 23-valent pneumococcal polysaccharide vaccine (23vPS) prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13 valent pneumococcal conjugate (13vPnC) administered as a single dose 0.5 milliliter (mL) intramuscularly (IM) at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)	130
13vPnC/23vPS Group (23vPS Naïve) Participants aged 60 to 64 years old who had never received 23vPS prior to enrollment into the parent study (NCT00574548), completed study NCT00574548 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 23vPS administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)	210
23vPS/13vPnC Group (23vPS Naïve) Participants aged 60 to 64 years old who had never been vaccinated with 23vPS prior to enrollment into the parent study (NCT00574548), who completed study NCT00574548 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)	179
13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior) Participants aged 70 years of age or greater previously vaccinated with 23vPS greater than or equal to (≥) 5 years before enrollment in the parent study (NCT00546572), who completed study NCT00546572 receiving 13vPnC administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and at Year 1 (Vaccination 2)	221
23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior) Participants aged 70 years of age or greater previously vaccinated with 23vPS ≥5 years before enrollment in the parent study (NCT00546572), who completed study NCT00546572 receiving 23vPS administered as a single dose 0.5 mL IM at Year 0 (Vaccination 1) and 13vPnC administered as a single dose 0.5 mL IM at Year 1 (Vaccination 2)	222
Total	962

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004
Overall Study	Protocol Violation	0	0	0	2	0

Baseline characteristics

Characteristic	13vPnC/13vPnC Group (23vPS Naïve)	13vPnC/23vPS Group (23vPS Naïve)	23vPS/13vPnC Group (23vPS Naïve)	13vPnC/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	23vPS/13vPnC Group (23vPS Vaccination ≥5 Years Prior)	Total
Age Continuous	64.0 Years STANDARD_DEVIATION 1.4	64.1 Years STANDARD_DEVIATION 1.4	64.2 Years STANDARD_DEVIATION 1.4	78.3 Years STANDARD_DEVIATION 4.5	77.8 Years STANDARD_DEVIATION 4.1	70.5 Years STANDARD_DEVIATION 7.6
Sex: Female, Male Female	76 Participants	125 Participants	102 Participants	114 Participants	115 Participants	532 Participants
Sex: Female, Male Male	54 Participants	85 Participants	77 Participants	107 Participants	107 Participants	430 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	0 / 130	0 / 210	0 / 179	0 / 221	0 / 222
serious Total, serious adverse events	0 / 130	0 / 210	0 / 179	0 / 221	0 / 222

Outcome results

Primary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)

Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CIs) for the GMTs are back transformations of a confidence interval based on the Student t distribution for the mean logarithm of the titers.

Time frame: Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with valid and determinate antibody titer for the specified serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 4	265 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 9V	81 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 6A	250 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 14	202 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 3	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 18C	540 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 6B	510 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 19A	232 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 5	58 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 19F	277 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 7F	173 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 23F	103 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 1	38 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 23F	45 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 1	22 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 3	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 4	172 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 5	42 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 6A	115 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 6B	381 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 7F	115 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 9V	68 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 14	240 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 18C	360 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 19A	181 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 in Parent Study 6115A1-3005 (NCT00546572)	Serotype 19F	158 titer

Primary

Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)

Time frame: Month 1/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population included all participants enrolled in 6115A1-3018 (NCT01025336) with a valid and determinate assay result who received both vaccinations in either parent study 6115A1-3010 (NCT00574548) or 6115A1-3005 (NCT00546572). N=number of participants with valid and determinate antibody titer for the specified serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 19F	256 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 14	379 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 6B	785 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 4	328 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 9V	211 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 7F	247 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 1	54 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 3	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 19A	244 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 5	29 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 23F	110 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 18C	393 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 6A	316 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 7F	412 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 1	52 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 3	27 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 4	355 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 5	76 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 6A	225 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 6B	593 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 9V	221 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 14	416 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 18C	527 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 19A	313 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 19F	426 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 23F	64 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 14	383 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 5	44 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 19F	195 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 18C	337 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 4	183 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 1	36 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 19A	170 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 7F	145 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 6B	324 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 3	18 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 9V	129 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 6A	102 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study 6115A1-3010 (NCT00574548)	Serotype 23F	35 titer

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)

Antibody GMTs as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). CI for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame: Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 4	328 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V	211 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A	316 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 14	379 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 3	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C	393 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B	785 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A	244 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 5	29 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F	256 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F	247 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F	110 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 1	54 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F	64 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 1	52 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 3	27 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 4	355 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 5	76 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A	225 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B	593 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F	412 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V	221 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 14	416 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C	527 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A	313 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 13vPnC/23vPS (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F	426 titer

Comparison: Serotype 1: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.72, 1.51]

Comparison: Serotype 3: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.52, 0.94]

Comparison: Serotype 4: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.58, 1.47]

Comparison: Serotype 5: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.25, 0.59]

Comparison: Serotype 6A: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.85, 2.32]

Comparison: Serotype 6B: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.82, 2.13]

Comparison: Serotype 7F: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.37, 0.97]

Comparison: Serotype 9V: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.54, 1.7]

Comparison: Serotype 14: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.59, 1.41]

Comparison: Serotype 18C: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.48, 1.17]

Comparison: Serotype 19A: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.58, 1.05]

Comparison: Serotype 19F: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.41, 0.88]

Comparison: Serotype 23F: Ratio of GMT (13vPnC/13vPnC to 13vPnC/23vPS) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.05, 2.81]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)

Time frame: Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 4	265 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V	81 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A	250 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 14	202 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 3	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C	540 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B	510 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A	232 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 5	58 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F	277 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F	173 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F	103 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 1	38 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F	45 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 1	22 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 3	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 4	172 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 5	42 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A	115 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B	381 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F	115 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V	68 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 14	240 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C	360 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A	181 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F	158 titer

Comparison: Serotype 1: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [1.27, 2.4]

Comparison: Serotype 3: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.95, 1.59]

Comparison: Serotype 4: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [1.03, 2.29]

Comparison: Serotype 5: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.95, 1.97]

Comparison: Serotype 6A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [1.42, 3.31]

Comparison: Serotype 6B: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.88, 2.04]

Comparison: Serotype 7F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.95, 2.4]

Comparison: Serotype 9V: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.7, 1.99]

Comparison: Serotype 14: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.57, 1.25]

Comparison: Serotype 18C: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [1.06, 2.12]

Comparison: Serotype 19A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [0.97, 1.69]

Comparison: Serotype 19F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [1.21, 2.53]

Comparison: Serotype 23F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale95% CI: [1.54, 3.42]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)

Time frame: Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 4	328 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V	211 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A	316 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 14	379 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 3	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C	393 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B	785 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A	244 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 5	29 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F	256 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F	247 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F	110 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 1	54 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F	35 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 1	36 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 3	18 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 4	183 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 5	44 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A	102 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B	324 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F	145 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V	129 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 14	383 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C	337 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A	170 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/13vPnC Compared to 23vPS/13vPnC (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F	195 titer

Comparison: Serotype 1: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.02, 2.25]

Comparison: Serotype 3: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.78, 1.44]

Comparison: Serotype 4: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.06, 3]

Comparison: Serotype 5: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.41, 1.04]

Comparison: Serotype 6A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.82, 5.24]

Comparison: Serotype 6B: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.43, 4.11]

Comparison: Serotype 7F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.96, 3]

Comparison: Serotype 9V: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.88, 3.04]

Comparison: Serotype 14: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.64, 1.54]

Comparison: Serotype 18C: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.71, 1.93]

Comparison: Serotype 19A: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.01, 2.04]

Comparison: Serotype 19F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.84, 2.06]

Comparison: Serotype 23F: Ratio of GMT (13vPnC/13vPnC to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.89, 5.2]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)

Time frame: Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 1	52 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 3	27 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 4	355 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 5	76 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 6A	225 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 6B	593 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 7F	412 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 9V	221 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 14	416 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 18C	527 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 19A	313 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 19F	426 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 23F	64 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 18C	337 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 1	36 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 7F	145 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 3	18 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 19F	195 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 4	183 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 9V	129 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 5	44 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 14	383 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 19A	170 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 6A	102 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 23F	35 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 for 13vPnC/23vPS Compared to 23vPS/13vPnC (Parent Study 6115A-3010; NCT00574548)	Serotype 6B	324 titer

Comparison: Serotype 1: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.02, 2.08]

Comparison: Serotype 3: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.14, 1.99]

Comparison: Serotype 4: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.22, 3.06]

Comparison: Serotype 5: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.15, 2.56]

Comparison: Serotype 6A: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.36, 3.53]

Comparison: Serotype 6B: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.15, 2.91]

Comparison: Serotype 7F: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.8, 4.44]

Comparison: Serotype 9V: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.99, 2.96]

Comparison: Serotype 14: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [0.73, 1.62]

Comparison: Serotype 18C: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.02, 2.39]

Comparison: Serotype 19A: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.38, 2.45]

Comparison: Serotype 19F: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.53, 3.12]

Comparison: Serotype 23F: Ratio of GMT (13vPnC/23vPS to 23vPS/13vPnC) was calculated by back transforming the mean difference between vaccine sequence on the logarithmic scale.95% CI: [1.18, 2.82]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

Time frame: Month 1/Year 0 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with valid and determinate assay results for the specified serotype at both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	165 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Month Post Vax 1	84 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Month Post Vax 1	193 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	58 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	82 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Month Post Vax 1	241 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Month Post Vax 1	975 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	205 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Month Post Vax 1	92 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Month Post Vax 1	946 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	264 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	544 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Month Post Vax 1	511 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Month Post Vax 1	381 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Month Post Vax 1	1331 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	232 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Month Post Vax 1	52 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Month Post Vax 1	407 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	553 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	281 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	271 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Month Post Vax 1	173 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Month Post Vax 1	328 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	106 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	39 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	45 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Month Post Vax 1	53 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	22 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Month Post Vax 1	51 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Month Post Vax 1	216 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	185 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	42 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Month Post Vax 1	106 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	115 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Month Post Vax 1	465 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	396 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Month Post Vax 1	195 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	112 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Month Post Vax 1	102 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	69 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Month Post Vax 1	280 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	236 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Month Post Vax 1	555 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	370 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Month Post Vax 1	199 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	180 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Month Post Vax 1	238 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	158 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Month Post Vax 1	48 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Month Post Vax 1	42 titer

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.36, 0.5]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.36, 0.48]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.33, 0.44]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.26, 0.37]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.42, 0.68]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.64, 1.14]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.6, 0.82]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.86, 1.18]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.22, 0.33]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.81, 1.46]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.34, 0.51]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.66, 1.09]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.37, 0.68]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.43, 0.77]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.3, 0.6]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.47, 0.98]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.72, 1.01]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.71, 1]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.5, 0.66]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.56, 0.8]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.54, 0.69]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.78, 1.05]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.59, 0.8]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.53, 0.83]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.51, 0.74]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.75, 1.15]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

Time frame: Month 1/Year 0 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Month Post Vax 1	153 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Month Post Vax 1	1603 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Month Post Vax 1	614 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Month Post Vax 1	698 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	409 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	26 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Month Post Vax 1	906 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	203 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	243 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	346 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Month Post Vax 1	2757 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Month Post Vax 1	530 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Month Post Vax 1	2546 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	231 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	239 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	855 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Month Post Vax 1	339 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	286 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Month Post Vax 1	75 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	105 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	387 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Month Post Vax 1	1055 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Month Post Vax 1	229 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Month Post Vax 1	1739 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	54 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Month Post Vax 1	801 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	47 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Month Post Vax 1	75 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Month Post Vax 1	1969 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	27 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Month Post Vax 1	2575 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	224 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	405 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Month Post Vax 1	255 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	69 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Month Post Vax 1	727 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Month Post Vax 1	3022 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	235 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	435 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	697 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Month Post Vax 1	1614 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	560 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Month Post Vax 1	1459 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	310 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Month Post Vax 1	781 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Month Post Vax 1	845 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	398 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Month Post Vax 1	367 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	416 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	70 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Month Post Vax 1	228 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	39 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Month Post Vax 1	767 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	319 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Month Post Vax 1	365 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	143 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Month Post Vax 1	294 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	127 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Month Post Vax 1	748 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	391 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Month Post Vax 1	888 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	323 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Month Post Vax 1	380 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	162 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Month Post Vax 1	423 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	180 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Month Post Vax 1	72 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	35 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Month Post Vax 1	147 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Month Post Vax 1	85 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	18 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Month Post Vax 1	1406 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	184 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Month Post Vax 1	145 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	45 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Month Post Vax 1	335 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	105 titer

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.25, 0.38]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.19, 0.29]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.17, 0.25]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.2, 0.29]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.2, 0.3]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.31, 0.42]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.18, 0.26]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.1, 0.18]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.12, 0.2]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.1, 0.18]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.13, 0.22]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.22, 0.33]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.08, 0.14]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.06, 0.1]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.22, 0.46]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.4, 0.6]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.29, 0.43]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.29, 0.59]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.17, 0.38]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.21, 0.36]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.27, 0.56]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.13, 0.28]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.2, 0.39]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.28, 0.67]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.48, 0.83]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.49, 0.74]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.42, 0.65]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.2, 0.32]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.28, 0.43]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.29, 0.45]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.3, 0.41]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.35, 0.45]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.36, 0.51]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.35, 0.58]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.39, 0.62]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.34, 0.54]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.23, 0.42]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.15, 0.24]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [0.42, 0.69]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)

Time frame: Month 1/Year 1 (Parent study/NCT00546572), Month 1/Year 2 (Follow-up Study/NCT01025336)

Population: All-Available Immunogenicity Population; N=number of participants with valid and determinate assay result for specified serotype at both 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Month Post Vax 2	62 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	39 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Month Post Vax 2	50 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Month Post Vax 2	437 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	311 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Month Post Vax 2	80 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	58 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Month Post Vax 2	1088 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	257 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Month Post Vax 2	1516 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	561 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Month Post Vax 2	233 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	173 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Month Post Vax 2	166 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	83 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Month Post Vax 2	216 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	209 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Month Post Vax 2	1015 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	553 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Month Post Vax 2	356 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	228 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Month Post Vax 2	349 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	274 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Month Post Vax 2	324 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	102 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	366 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Month Post Vax 2	34 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	117 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	22 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Month Post Vax 2	113 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Month Post Vax 2	32 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Month Post Vax 2	91 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Month Post Vax 2	255 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Month Post Vax 2	237 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	73 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	186 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	158 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Month Post Vax 2	49 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Month Post Vax 2	199 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	42 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	182 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Month Post Vax 2	569 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	244 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	133 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	46 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Month Post Vax 2	781 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Month Post Vax 2	523 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	381 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Month Post Vax 2	178 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Month Post Vax 2	135 titer

Comparison: Serotype 1: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.42, 0.56]

Comparison: Serotype 3: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.35, 0.45]

Comparison: Serotype 4: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.6, 0.85]

Comparison: Serotype 5: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.81, 1.08]

Comparison: Serotype 6A: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.19, 0.29]

Comparison: Serotype 6B: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.31, 0.45]

Comparison: Serotype 7F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.58, 0.96]

Comparison: Serotype 9V: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.37, 0.67]

Comparison: Serotype 14: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.85, 1.09]

Comparison: Serotype 18C: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.48, 0.62]

Comparison: Serotype 19A: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.57, 0.72]

Comparison: Serotype 19F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.66, 0.93]

Comparison: Serotype 23F: Geometric mean fold rises (GMFRs) were calculated using all subjects with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.27, 0.37]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)

Time frame: Month 1/Year 1 (Parent study/NCT00574548), Month 1/Year 2 (Follow-up Study/NCT01025336)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Month Post Vax 2	95 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	54 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Month Post Vax 2	87 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	18 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Month Post Vax 2	1284 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	318 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Month Post Vax 2	141 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	29 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Month Post Vax 2	2120 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	304 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Month Post Vax 2	1683 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	847 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Month Post Vax 2	306 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	237 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Month Post Vax 2	385 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	221 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Month Post Vax 2	434 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	380 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Month Post Vax 2	972 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	373 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Month Post Vax 2	365 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	213 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Month Post Vax 2	493 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	255 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Month Post Vax 2	543 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	108 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Month Post Vax 2	1307 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Month Post Vax 2	513 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	266 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Month Post Vax 2	1232 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Month Post Vax 2	218 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	637 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	295 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Month Post Vax 2	667 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	412 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Month Post Vax 2	419 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Month Post Vax 2	835 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	224 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Month Post Vax 2	639 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	406 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Month Post Vax 2	149 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	52 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	425 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Month Post Vax 2	130 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Month Post Vax 2	1092 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	27 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Month Post Vax 2	1375 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	369 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	513 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Month Post Vax 2	223 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	72 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	63 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Month Post Vax 2	80 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Month Post Vax 2	898 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Month Post Vax 2	70 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	115 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Month Post Vax 2	282 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	388 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Month Post Vax 2	740 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	197 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	36 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	352 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	331 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	203 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Month Post Vax 2	131 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	167 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Month Post Vax 2	50 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	148 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Month Post Vax 2	109 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Month Post Vax 2	933 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Month Post Vax 2	122 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	41 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	18 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	139 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Month Post Vax 2	264 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Month Post Vax 2	549 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Month Post Vax 2	426 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to 1 Month After Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	38 titer

Comparison: Serotype 1: Geometric mean fold rise (GMFR) was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.32, 0.46]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.3, 0.41]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.44, 0.61]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.17, 0.25]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.18, 0.24]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.31, 0.41]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.19, 0.32]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.22, 0.33]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.17, 0.3]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.25, 0.39]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.27, 0.38]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.44, 0.6]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.1, 0.2]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.17, 0.25]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.09, 0.16]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.41, 0.62]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.43, 0.62]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.38, 0.59]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.6, 1]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.51, 0.75]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.86, 1.46]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.41, 0.8]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.39, 0.73]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.78, 1.67]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.71, 1.08]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.54, 0.75]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.78, 1.06]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.29, 0.51]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.39, 0.56]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.53, 0.69]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.49, 0.69]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.52, 0.63]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.53, 0.66]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.42, 0.64]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.44, 0.6]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.63, 0.88]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.15, 0.26]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.23, 0.35]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the 1 Month Postvaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.28, 0.43]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

Time frame: Month 0/Year 0 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with valid and determinate assay results for the specified serotype at both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, Pre Vax 1	12 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	38 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, Pre Vax 1	9 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, Pre Vax 1	30 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	238 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, Pre Vax 1	10 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	57 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, Pre Vax 1	22 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	259 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, Pre Vax 1	79 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	507 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, Pre Vax 1	23 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	169 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, Pre Vax 1	21 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	75 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, Pre Vax 1	70 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	202 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, Pre Vax 1	131 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	530 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, Pre Vax 1	79 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	236 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, Pre Vax 1	46 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	272 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, Pre Vax 1	14 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F 1 Year Post Vax 2	99 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	368 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, Pre Vax 1	10 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	115 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	22 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, Pre Vax 1	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, Pre Vax 1	10 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, Pre Vax 1	23 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, Pre Vax 1	66 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, Pre Vax 1	27 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	66 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	160 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	151 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, Pre Vax 1	14 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, Pre Vax 1	79 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	43 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	175 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, Pre Vax 1	31 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	224 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	108 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F 1 Year Post Vax 2	45 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, Pre Vax 1	123 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, Pre Vax 1	145 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	385 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, Pre Vax 1	37 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, Pre Vax 1	21 titer

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.05, 4.49]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [1.92, 2.81]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [1.83, 2.5]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [1.32, 1.74]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.82, 11.09]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.25, 8.21]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.96, 6]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.58, 3.79]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.56, 16.49]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.59, 4.76]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.61, 9.03]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.32, 4.24]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.23, 10.33]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.07, 7.69]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.5, 5.2]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.1, 4.04]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.26, 3.71]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.23, 3.63]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.16, 5.2]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.06, 3.14]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.46, 3.6]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.24, 3.15]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.55, 7.76]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.13, 5.17]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.16, 9.25]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.24, 3.4]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)

Time frame: Month 0/Year 0 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, Pre Vax 1	21 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	237 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, Pre Vax 1	27 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	313 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, Pre Vax 1	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	187 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, Pre Vax 1	35 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, Pre Vax 1	15 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	720 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	114 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	238 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, Pre Vax 1	7 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	245 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, Pre Vax 1	24 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	54 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, Pre Vax 1	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	314 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, Pre Vax 1	7 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	400 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, Pre Vax 1	5 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, Pre Vax 1	10 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, Pre Vax 1	20 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	29 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, Pre Vax 1	6 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	350 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	192 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, Pre Vax 1	6 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	52 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, Pre Vax 1	6 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	27 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, Pre Vax 1	36 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	323 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, Pre Vax 1	6 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	75 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, Pre Vax 1	17 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	214 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, Pre Vax 1	24 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	522 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, Pre Vax 1	8 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	384 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, Pre Vax 1	15 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, Pre Vax 1	34 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	385 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, Pre Vax 1	25 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	546 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, Pre Vax 1	25 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	327 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, Pre Vax 1	24 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	415 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, Pre Vax 1	9 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	59 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, Pre Vax 1	46 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	43 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, Pre Vax 1	7 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	366 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, Pre Vax 1	6 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, Pre Vax 1	7 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, Pre Vax 1	33 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	170 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	186 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	324 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, Pre Vax 1	31 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	36 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, Pre Vax 1	21 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	17 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, Pre Vax 1	7 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	292 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	34 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	143 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, Pre Vax 1	26 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	162 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, Pre Vax 1	18 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	94 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, Pre Vax 1	16 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	119 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, Pre Vax 1	14 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 1 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, Pre Vax 1	7 titer

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [6.05, 10.67]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [6.65, 10.45]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.71, 6.14]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.59, 3.91]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.67, 5.26]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [2.2, 3.14]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [7.8, 21.34]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [6.26, 12.92]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.71, 8.07]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.35, 8.8]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [9.71, 16.3]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.59, 10.02]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [9.56, 23.81]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.66, 17.38]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.29, 9.89]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [12.59, 34.24]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [14.56, 31.46]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [7.24, 17.01]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [19.75, 52.57]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [34, 65.43]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [12.95, 29.17]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [7.79, 21.13]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.56, 18.68]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [4.54, 10.1]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.16, 20.02]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.15, 16.23]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.75, 11.25]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [12.99, 30.76]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [16.5, 30.06]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [7.07, 13.63]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.82, 16.34]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [10.21, 16.66]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.86, 9.94]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.05, 18.34]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [12.77, 23.24]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [8.01, 16.45]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [7.89, 18.19]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [5.02, 8.92]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 1 and 1 Year Postvaccination 2 blood draws.95% CI: [3.52, 6.29]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)

Time frame: Month 0/Year 1 (Parent Study NCT00546572), Month 1/Year 2 (Follow-up Study NCT01025336)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, Pre Vax 2	32 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	38 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, Pre Vax 2	16 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, Pre Vax 2	129 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	267 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, Pre Vax 2	33 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	57 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, Pre Vax 2	279 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	256 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, Pre Vax 2	403 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	511 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, Pre Vax 2	66 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	175 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, Pre Vax 2	40 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	76 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, Pre Vax 2	130 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	204 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, Pre Vax 2	436 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	545 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, Pre Vax 2	185 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	235 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, Pre Vax 2	121 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	261 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, Pre Vax 2	60 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	104 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	360 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, Pre Vax 2	21 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	111 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	22 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, Pre Vax 2	30 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, Pre Vax 2	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, Pre Vax 2	28 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	16 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, Pre Vax 2	124 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, Pre Vax 2	73 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	69 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	177 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	159 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, Pre Vax 2	24 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, Pre Vax 2	144 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	42 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	181 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, Pre Vax 2	58 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	240 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	113 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	46 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, Pre Vax 2	186 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, Pre Vax 2	271 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	361 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, Pre Vax 2	84 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, Pre Vax 2	66 titer

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.03, 1.31]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.91, 1.16]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.07, 1.37]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.91, 1.13]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.6, 2.68]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.82, 3.24]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.55, 2.03]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.54, 2.09]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.79, 1.07]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.48, 2.55]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.05, 1.53]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.5, 2.51]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.98, 3.5]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.31, 2.18]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.37, 2.61]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.76, 3.38]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.33, 1.86]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.38, 2.01]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.1, 1.42]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.14, 1.55]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.14, 1.43]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.28, 1.67]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.8, 2.6]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.53, 2.31]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.44, 2.06]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.24, 1.84]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)

Time frame: Month 0/Year 1 (Parent Study NCT00574548), Month 1/Year 2 (Follow-up Study NCT01025336)

Population: All-Available Immunogenicity Population; N=number of participants with valid and determinate assay result for specified serotype at both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, Pre Vax 2	39 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	52 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, Pre Vax 2	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	18 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, Pre Vax 2	710 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	376 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, Pre Vax 2	52 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	29 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, Pre Vax 2	540 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	331 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, Pre Vax 2	459 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	781 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, Pre Vax 2	146 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	244 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, Pre Vax 2	96 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	201 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, Pre Vax 2	241 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	383 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, Pre Vax 2	403 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	398 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, Pre Vax 2	203 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	253 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, Pre Vax 2	114 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	238 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, Pre Vax 2	90 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	104 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, Pre Vax 2	656 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, Pre Vax 2	209 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	251 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, Pre Vax 2	430 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, Pre Vax 2	90 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	580 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	296 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, Pre Vax 2	133 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	414 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, Pre Vax 2	79 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, Pre Vax 2	183 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	212 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, Pre Vax 2	290 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	420 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, Pre Vax 2	56 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	50 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	419 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, Pre Vax 2	23 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, Pre Vax 2	462 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	26 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, Pre Vax 2	591 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	414 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	513 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, Pre Vax 2	66 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	73 titer
13vPnC/23vPS Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	66 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, Pre Vax 2	49 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, Pre Vax 2	350 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, Pre Vax 2	44 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, 1 Year Post Vax 2	108 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, Pre Vax 2	153 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, 1 Year Post Vax 2	367 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, Pre Vax 2	192 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, 1 Year Post Vax 2	190 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 1, 1 Year Post Vax 2	34 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6B, 1 Year Post Vax 2	298 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, 1 Year Post Vax 2	349 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 4, 1 Year Post Vax 2	209 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, Pre Vax 2	71 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19A, 1 Year Post Vax 2	169 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, Pre Vax 2	26 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 7F, 1 Year Post Vax 2	146 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, Pre Vax 2	30 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 6A, Pre Vax 2	85 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, Pre Vax 2	50 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 5, 1 Year Post Vax 2	43 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 3, 1 Year Post Vax 2	18 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 9V, 1 Year Post Vax 2	147 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 19F, Pre Vax 2	127 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 18C, Pre Vax 2	339 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 14, Pre Vax 2	302 titer
23vPS/13vPnC Group (23vPS Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence 1 Year After Vaccination 2 Relative to Before Vaccination 2 (Parent Study 6115A1-3010; NCT00574548)	Serotype 23F, 1 Year Post Vax 2	36 titer

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.85, 1.22]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.79, 1.02]

Comparison: Serotype 1: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.69, 0.9]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.82, 1.1]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.98, 1.32]

Comparison: Serotype 3: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.62, 0.81]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.41, 0.69]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.6, 0.82]

Comparison: Serotype 4: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.47, 0.76]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.67, 0.87]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.96, 1.3]

Comparison: Serotype 5: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.75, 1.02]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.48, 0.79]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.32, 0.46]

Comparison: Serotype 6A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.94, 1.75]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.32, 2.19]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.14, 1.6]

Comparison: Serotype 6B: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.2, 2.01]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.24, 2.26]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [2.26, 4.3]

Comparison: Serotype 7F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.53, 2.75]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.48, 2.95]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.97, 3.7]

Comparison: Serotype 9V: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.99, 4.29]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.23, 2.05]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.18, 1.78]

Comparison: Serotype 14: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.04, 1.42]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.82, 1.19]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.96, 1.29]

Comparison: Serotype 18C: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.89, 1.2]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.07, 1.46]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.24, 1.61]

Comparison: Serotype 19A: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.96, 1.27]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.56, 2.8]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.82, 2.88]

Comparison: Serotype 19F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [1.18, 1.9]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.89, 1.48]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.63, 0.85]

Comparison: Serotype 23F: GMFR was calculated using all participants with available data from both the Prevaccination 2 and 1 Year Postvaccination 2 blood draws.95% CI: [0.99, 1.51]

Secondary

Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)

Time frame: Month 0/Year 1 (Parent Study NCT00546572), Month 0/Year 2 (Baseline) (Follow-up Study 6115A1-3018; NCT01025336)

Population: All-Available Immunogenicity Population. N=number of participants with a determinate OPA antibody titer to the given serotype.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, Pre Vax 2	33 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 1, 1 Year Post Vax 2	38 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, Pre Vax 2	16 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 3, 1 Year Post Vax 2	19 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, Pre Vax 2	129 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 4, 1 Year Post Vax 2	267 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, Pre Vax 2	32 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 5, 1 Year Post Vax 2	57 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, Pre Vax 2	279 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6A, 1 Year Post Vax 2	256 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, Pre Vax 2	403 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 6B, 1 Year Post Vax 2	511 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, Pre Vax 2	66 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 7F, 1 Year Post Vax 2	175 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, Pre Vax 2	40 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 9V, 1 Year Post Vax 2	76 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, Pre Vax 2	130 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 14, 1 Year Post Vax 2	204 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, Pre Vax 2	436 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 18C, 1 Year Post Vax 2	545 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, Pre Vax 2	185 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19A, 1 Year Post Vax 2	235 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, Pre Vax 2	121 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 19F, 1 Year Post Vax 2	261 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, Pre Vax 2	60 titer
13vPnC/13vPnC Group (23vPs Naïve)	Serotype-Specific Pneumococcal OPA GMT Antibody Persistence for 13vPnC/13vPnC 1 Year After Vaccination 2 Compared to 13vPnC/13vPnC After Vaccination 1 (Parent Study 6115A1-3005; NCT00546572)	Serotype 23F, 1 Year Post Vax 2	104 titer